Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Devan V Mehrotra

Showing results (51-60 of 76) with videos related to

Pageof 8
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 8, 2008
HIV seroconversion without infection after receipt of adenovirus-vectored HIV type 1 vaccineErin K Quirk, Robin Mogg, Deborah D Brown, et al.
Open Forum Infectious Diseases|March 4, 2015
Safety Profile of the Merck Human Immunodeficiency Virus-1 Clade B gag DNA Plasmid Vaccine With and Without AdjuvantsErin K Quirk, Elizabeth L Brown, Randi Y Leavitt, et al.
American Journal of Human Genetics|February 23, 2022
GWAS of longitudinal trajectories at biobank scaleSeyoon Ko, Christopher A German, Aubrey Jensen, et al.
Immunity|January 5, 2022
Germline HLA landscape does not predict efficacy of pembrolizumab monotherapy across solid tumor typesAparna Chhibber, Lingkang Huang, Hong Zhang, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 24, 2011
Impact of herpes simplex virus type 2 on HIV-1 acquisition and progression in an HIV vaccine trial (the Step study)Ruanne V Barnabas, Judith N Wasserheit, Yunda Huang, et al.
The Journal of Infectious Diseases|January 19, 2007
Estimating the benefit of an HIV-1 vaccine that reduces viral load set pointSwati B Gupta, Lisa P Jacobson, Joseph B Margolick, et al.
Pharmacogenomics|June 29, 2019
The pharmacogenetics of OATP1B1 variants and their impact on the pharmacokinetics and efficacy of elbasvir/grazoprevirZifang Guo, Luzelena Caro, Michael N Robertson, et al.
Clinical and Vaccine Immunology : CVI|July 17, 2009
Safety and immunogenicity of the Merck adenovirus serotype 5 (MRKAd5) and MRKAd6 human immunodeficiency virus type 1 trigene vaccines alone and in combination in healthy adultsClayton Harro, Xiao Sun, Jon E Stek, et al.
Msphere|May 8, 2020
Genetic Association Reveals Protection against Recurrence of <i>Clostridium difficile</i> Infection with Bezlotoxumab TreatmentJudong Shen, Devan V Mehrotra, Mary Beth Dorr, et al.
AIDS Research and Human Retroviruses|December 7, 2006
A comparison of standard immunogenicity assays for monitoring HIV type 1 gag-specific T cell responses in Ad5 HIV Type 1 gag vaccinated human subjectsTimothy W Tobery, Sheri A Dubey, Kiersten Anderson, et al.
Pageof 8

Showing results (51-60 of 76) with videos related to

Sort By:
Pageof 8
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 8, 2008
HIV seroconversion without infection after receipt of adenovirus-vectored HIV type 1 vaccineErin K Quirk, Robin Mogg, Deborah D Brown, et al.
Open Forum Infectious Diseases|March 4, 2015
Safety Profile of the Merck Human Immunodeficiency Virus-1 Clade B gag DNA Plasmid Vaccine With and Without AdjuvantsErin K Quirk, Elizabeth L Brown, Randi Y Leavitt, et al.
American Journal of Human Genetics|February 23, 2022
GWAS of longitudinal trajectories at biobank scaleSeyoon Ko, Christopher A German, Aubrey Jensen, et al.
Immunity|January 5, 2022
Germline HLA landscape does not predict efficacy of pembrolizumab monotherapy across solid tumor typesAparna Chhibber, Lingkang Huang, Hong Zhang, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 24, 2011
Impact of herpes simplex virus type 2 on HIV-1 acquisition and progression in an HIV vaccine trial (the Step study)Ruanne V Barnabas, Judith N Wasserheit, Yunda Huang, et al.
The Journal of Infectious Diseases|January 19, 2007
Estimating the benefit of an HIV-1 vaccine that reduces viral load set pointSwati B Gupta, Lisa P Jacobson, Joseph B Margolick, et al.
Pharmacogenomics|June 29, 2019
The pharmacogenetics of OATP1B1 variants and their impact on the pharmacokinetics and efficacy of elbasvir/grazoprevirZifang Guo, Luzelena Caro, Michael N Robertson, et al.
Clinical and Vaccine Immunology : CVI|July 17, 2009
Safety and immunogenicity of the Merck adenovirus serotype 5 (MRKAd5) and MRKAd6 human immunodeficiency virus type 1 trigene vaccines alone and in combination in healthy adultsClayton Harro, Xiao Sun, Jon E Stek, et al.
Msphere|May 8, 2020
Genetic Association Reveals Protection against Recurrence of <i>Clostridium difficile</i> Infection with Bezlotoxumab TreatmentJudong Shen, Devan V Mehrotra, Mary Beth Dorr, et al.
AIDS Research and Human Retroviruses|December 7, 2006
A comparison of standard immunogenicity assays for monitoring HIV type 1 gag-specific T cell responses in Ad5 HIV Type 1 gag vaccinated human subjectsTimothy W Tobery, Sheri A Dubey, Kiersten Anderson, et al.
Pageof 8